Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENT103 Phase 3 Study in Suppurative Otitis Media with Persistent or Prolonged Otorrhea
jRCT2080224658Phase 3Completed
- Sponsor
- CEOLIA Pharma
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute otitis media (AOM), chronic suppurative otitis media (CSOM) and otorrhea comparing ENT103 with Placebo (2 arms). Started Apr 2019; status: completed.
02
Drugs
ciprofloxacin + dexamethasone
03
Conditions
acute otitis media (AOM)chronic suppurative otitis media (CSOM)otorrhea
Beyond the preview
Go deeper on jRCT2080224658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224658.